Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02469701 · ClinicalTrials.gov registry record · Phase 2
Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease
A Phase 2 study, sponsored by howard safran.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02469701 is a Phase 2 study that was terminated before completion, run by howard safran. The registered enrollment target is 10 participants.
The verdict
NCT02469701, a Phase 2 study, was terminated before completion, sponsored by howard safran.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
Nivolumab releases the inhibition of the immune system against human cancers. Dramatic and sustained activity has been observed in advanced lung cancer. Ablation may stimulate the immune system by exposing new tumor antigens. Since tumors that express PD-L1 may be more likely to respond to nivolumab, if ablation increases PD-L1 expression (which has not been studied) this treatment may enhance the activity of nivolumab at both the treated site and in other, non-treated, tumors. Ablation is already an FDA approved treatment for cancer. Nivolumab was recently FDA approved for second line treatment of advanced squamous cell NSCLC. The goal of the study will be to determine if the combination of nivolumab and ablation has higher systemic activity than previously reported with nivolumab alone.
Interventions
- DRUG nivolumab and ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-02 |
| Est. Completion | 2018-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02469701
The ClinicalTrials.gov registry entry for NCT02469701 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is howard safran, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nivolumab and ablation is the first listed.
NCT02469701 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02469701 about?
NCT02469701 is a clinical study titled "Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease". Nivolumab releases the inhibition of the immune system against human cancers. Dramatic and sustained activity has been observed in advanced lung cancer. Ablation may stimulate the immune system by exposing new tumor antigens. Since tumors that express PD-L1 may be more likely to respond to nivolumab...
What is the current status of trial NCT02469701?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2016-02. Estimated completion is 2018-03.
What interventions are being tested in trial NCT02469701?
The interventions under investigation include: nivolumab and ablation (DRUG).
Who is sponsoring clinical trial NCT02469701?
This trial is sponsored by howard safran, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.